Posted by Michael Wonder on 13 Oct 2025
US FDA approves updated indication statement for Rinvoq (upadacitinib) for the treatment of inflammatory bowel disease
13 October 2025 - Updated indication allows the use of Rinvoq (upadacitinib) prior to the use of tumour necrosis factor blocking agents in patients for whom use of these treatments is clinically inadvisable and who have received at least one approved systemic therapy.
AbbVie today announced the US FDA approval of a supplemental new drug application (sNDA) that updates the indication statement for Rinvoq (upadacitinib) for the treatment of adults with moderately to severely active ulcerative colitis and moderately to severely active Crohn's disease.
